ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,037.88
      0.72%
      US Tech 100
      20,916.80
      0.93%
      Dow Jones
      44,556.04
      0.30%
      Brent Oil
      75.66
      -0.37%
      Bitcoin
      98,250.01
      0.40%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Immutep Ltd (IMMP) Quote

      Immutep Ltd

      Immutep Ltd (IMMP)

      NASDAQ
      1.95
      -0.02
      (-1.02%)
      Closed February 04 4:00PM
      Delayed by 15 minutes
      2.04
      0.09
      (4.62%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.95
      Bid
      1.95
      Ask
      2.03
      Volume
      33,171
      1.95 Day's Range 2.0445
      0.00 52 Week Range 0.00
      Market Cap
      283.641M
      Previous Close
      1.97
      Open
      2.00
      Last Trade
      10
      @
      2.0299
      Last Trade Time
      Financial Volume
      $ 66,375
      VWAP
      2.001
      Average Volume (3m)
      -
      Shares Outstanding
      145,456,785
      Dividend Yield
      -
      PE Ratio
      -1.09
      Earnings Per Share (EPS)
      -0.29
      Revenue
      -
      Net Profit
      -42.72M

      About Immutep Ltd

      Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.immutep.com
      Headquarters
      Sydney, New South Wales, Aus
      Founded
      -
      Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was $1.97. Over the last year, Immutep shares have traded in a share price range of $ 0.00 to $ 0.00.

      Immutep currently has 145,456,785 shares outstanding. The market capitalization of Immutep is $286.55 million. Immutep has a price to earnings ratio (PE ratio) of -1.09.

      Ask ADVFN Intelligence (AI)

      IMMP Latest News

      More News

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      February 03 2025
      Edgar (US Regulatory)

      Immutep Quarterly Activities Report Q2 FY25

      Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory...

      January 31 2025
      GlobeNewswire Inc.

      Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

      Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patientsData updates from...

      January 22 2025
      GlobeNewswire Inc.

      Patient Enrolment Completed for INSIGHT-003

      Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable...

      January 06 2025
      GlobeNewswire Inc.

      Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

      Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first...

      December 17 2024
      GlobeNewswire Inc.

      Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

      Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s...

      December 16 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      December 12 2024
      Edgar (US Regulatory)

      Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

      Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients...

      December 12 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      December 10 2024
      Edgar (US Regulatory)

      Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

      Media Release SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

      December 10 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      IMMP - Frequently Asked Questions (FAQ)

      What is the current Immutep share price?
      The current share price of Immutep is $ 1.95
      How many Immutep shares are in issue?
      Immutep has 145,456,785 shares in issue
      What is the market cap of Immutep?
      The market capitalisation of Immutep is USD 286.55M
      What is the 1 year trading range for Immutep share price?
      Immutep has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the PE ratio of Immutep?
      The price to earnings ratio of Immutep is -1.09
      What is the reporting currency for Immutep?
      Immutep reports financial results in AUD
      What is the latest annual profit for Immutep?
      The latest annual profit of Immutep is AUD -42.72M
      What is the registered address of Immutep?
      The registered address for Immutep is LEVEL 12, 95 PITT STREET, SYDNEY, NEW SOUTH WALES, 2000
      What is the Immutep website address?
      The website address for Immutep is www.immutep.com
      Which industry sector does Immutep operate in?
      Immutep operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CAPTCaptiVision Inc
      $ 1.024
      (133.26%)
      		245.99M
      QNTMQuantum Biopharma Ltd
      $ 6.70
      (110.69%)
      		78.56M
      LTRYLottery com Inc
      $ 0.58
      (85.90%)
      		129.21M
      CPIXCumberland Pharmaceutical Inc
      $ 3.7801
      (77.47%)
      		18.49M
      INKTMiNK Therapeutics Inc
      $ 12.08
      (53.69%)
      		350.86k
      OMGAOmega Therapeutics Inc
      $ 0.1473
      (-69.25%)
      		11.7M
      VIRXViracta Therapeutics Inc
      $ 0.0352
      (-54.76%)
      		6.33M
      CYNCYNGN Inc
      $ 0.0708
      (-39.44%)
      		137.27M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2663
      (-36.20%)
      		1.9M
      CSAICloudastructure Inc
      $ 12.98
      (-31.68%)
      		57.03k
      NVDANVIDIA Corporation
      $ 118.65
      (1.71%)
      		247.88M
      CAPTCaptiVision Inc
      $ 1.024
      (133.26%)
      		245.98M
      PLTRPalantir Technologies Inc
      $ 103.83
      (23.99%)
      		212.8M
      RGTIRigetti Computing Inc
      $ 13.71
      (1.78%)
      		150.62M
      CYNCYNGN Inc
      $ 0.0708
      (-39.44%)
      		134.49M

      IMMP Discussion

      View Posts
      Monksdream Monksdream 5 months ago
      IMMP 10 day hourly
      👍️0
      Monksdream Monksdream 7 months ago
      IMMP under $2
      👍️0
      Vector2112 Vector2112 7 months ago
      Refinitiv Logo
      As of 06/27/2024

      SellUnderperformHoldOutperformSelected Value:Buy
      Refinitiv Stock Reports Plus
      Refinitiv maintains a current price target of $8.64 for IMMP.
      👍️0
      glenn1919 glenn1919 7 months ago
      IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 7 months ago
      IMMP under $2
      👍️0
      Monksdream Monksdream 9 months ago
      IMMP under $3
      👍️0
      Monksdream Monksdream 1 year ago
      IMMP under $2
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      strong
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      ready
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      strong
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      watching
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      watching
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      dip
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      dip
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      im in my bio DRMA, one at a time


      RIGL rip for more
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      beast
      👍️0
      DewDiligence DewDiligence 2 years ago
      IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

      https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

      IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

      BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

      Please see #msg-168259768 for related info.
      👍️0
      Invest-in-America Invest-in-America 2 years ago
      IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

      👍️0
      stocks2watch stocks2watch 3 years ago
      Going to move up
      👍️0
      make it happen make it happen 4 years ago
      It's cool covered most average was $3.68
      👍️0
      calahan67 calahan67 4 years ago
      I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
      👍️0
      make it happen make it happen 4 years ago
      More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 6.35M
      Revenue Per Share (ttm) 0.14
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -17.07M
      Net Income Avi to Common (ttm) -27.36M
      Diluted EPS (ttm) -0.4500

      Total Debt (mrq) 9.75M
      Book Value Per Share (mrq) 0.94

      Cash Flow Statement
      Operating Cash Flow (ttm) -14.67M
      Levered Free Cash Flow (ttm) -7.67M
      👍️0
      sgunderbarth sgunderbarth 4 years ago
      IMMP Interesting action....
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $IMMP Video Chart 04-08-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      make it happen make it happen 4 years ago
      Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

      IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 4.85M
      Revenue Per Share (ttm) 0.11
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -13.03M
      Net Income Avi to Common (ttm) -20.89M
      Diluted EPS (ttm) -0.4600

      Balance Sheet
      Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
      Total Debt (mrq) 7.45M
      Book Value Per Share (mrq) 0.71

      Cash Flow Statement
      Operating Cash Flow (ttm) -11.2M
      Levered Free Cash Flow (ttm) -5.86M
      👍️0
      make it happen make it happen 4 years ago
      Had R/S a couple years ago and was $0.53 about a year ago
      👍️0
      make it happen make it happen 4 years ago
      Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 4.85M
      Revenue Per Share (ttm) 0.11
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -13.03M
      Net Income Avi to Common (ttm) -20.89M
      Diluted EPS (ttm) -0.4600

      Balance Sheet
      Total Cash Per Share (mrq) 0.65
      Total Debt (mrq) 7.45M
      Book Value Per Share (mrq) 0.71

      Cash Flow Statement
      Operating Cash Flow (ttm) -11.2M
      Levered Free Cash Flow (ttm) -5.86M
      👍️0
      make it happen make it happen 4 years ago
      I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
      👍️0
      reverse_long reverse_long 4 years ago
      IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
      👍️0
      calahan67 calahan67 4 years ago
      This is the real deal folks
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $IMMP Video Chart 03-25-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      DewDiligence DewDiligence 4 years ago
      IMMP up on BMY's LAG-3 coattails: #msg-162784750.
      👍️0
      calahan67 calahan67 4 years ago
      And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
      👍️0
      calahan67 calahan67 4 years ago
      Up huge on no news a great big sleeper imo
      👍️0
      calahan67 calahan67 4 years ago
      Looks like accumulation is beginning a slow churn higher
      👍️0
      everything everything 4 years ago
      Interesting company, looks to be in reversal but dip opportunity may be in the works.
      👍️0
      akamaii akamaii 4 years ago
      Like it here
      👍️0
      lecorb lecorb 4 years ago
      $IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
      👍️0

      Your Recent History

      NASDAQ
      IMMP
      Immutep
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads